



Apr 22, 2024

Mitochondrial DNA base editing in HEK293T cells

DOI

dx.doi.org/10.17504/protocols.io.yxmvm3rnol3p/v1

Nicole Lake¹, Kaiyue Ma¹, Justin Cohen¹, Monkol Lek¹

¹Department of Genetics, Yale School of Medicine, New Haven, CT, USA.



Justin Cohen

Yale School of Medicine

Create & collaborate more with a free account

Edit and publish protocols, collaborate in communities, share insights through comments, and track progress with run records.

Create free account

OPEN  ACCESS



DOI: <https://dx.doi.org/10.17504/protocols.io.yxmvm3rnol3p/v1>

Protocol Citation: Nicole Lake, Kaiyue Ma, Justin Cohen, Monkol Lek 2024. Mitochondrial DNA base editing in HEK293T cells. **protocols.io** <https://dx.doi.org/10.17504/protocols.io.yxmvm3rnol3p/v1>

Manuscript citation:

Lake NJ, et al. Quantifying constraint in the human mitochondrial genome. bioRxiv (2023). <https://doi.org/10.1101/2022.12.16.520778>

License: This is an open access protocol distributed under the terms of the **Creative Commons Attribution License**, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited



Protocol status: Working

We use this protocol and it's working

Created: February 12, 2024

Last Modified: April 22, 2024

Protocol Integer ID: 95136

Keywords: DdCBE, Base Editor, Mitochondria, Transfection, HEK293, mitochondrial dna base editing, cytosine base editor, derived cytosine base editor, ddcbe half, enrichment of cell, ddcbe, dna, right plasmid, dual plasmid system

Abstract

This protocol is for the transfection of mitochondrial-targeted DddA-derived cytosine base editors (DdCBE), and their subsequent selection, in HEK293T cells. This uses a dual plasmid system, where a 'left' and 'right' DdCBE are needed for editing. Enrichment of cells with both DdCBE halves is achieved by separate drug selection for the left and right plasmids.

Materials

HEK293 cells (ATCC, CRL-3216)

HEK media

- DMEM DMEM (Gibco, 11965092)
- 10% FBS (R&D Systems S11150)
- No antibiotics

DdCBE plasmids:

- Left/left-dead (blastR) and Right (PuroR)

Lipofectamine 3000 reagents (ThermoFisher, L3000008)

Opti-Mem I reduced serum medium (ThermoFisher, 31985070)

12-well tissue culture plates (Corning, 353043)

Blasticidin (ThermoFisher, A1113903)

Puromycin (ThermoFisher, A1113803)



Protocol materials

☒ HEK293T **ATCC Catalog #CRL-3216**

☒ Blasticidin S HCl (10 mg/mL) **Thermo Fisher Catalog #A1113903**

☒ Puromycin Dihydrochloride **Thermo Fisher Catalog #A1113803**

☒ Lipofectamine™ 3000 Transfection Reagent **Thermo Fisher Scientific Catalog #L3000008**

☒ Blasticidin S HCl (10 mg/mL) **Thermo Fisher Catalog #A1113903**

☒ Puromycin Dihydrochloride **Thermo Fisher Catalog #A1113803**

☒ DMEM, high glucose **Thermo Fisher Scientific Catalog #11965092**

☒ Fetal Bovine Serum (FBS) **ATCC Catalog #30-2020**

☒ DMEM, high glucose **Thermo Fisher Scientific Catalog #11965092**

☒ Fetal Bovine Serum (FBS) **ATCC Catalog #30-2020**

☒ DMEM, high glucose **Thermo Fisher Scientific Catalog #11965092**

☒ Fetal Bovine Serum (FBS) **ATCC Catalog #30-2020**

☒ Lipofectamine™ 3000 Transfection Reagent **Thermo Fisher Scientific Catalog #L3000008**

☒ Opti-MEM™ I Reduced Serum Medium **Thermo Fisher Scientific Catalog #31985070**

☒ Fetal Bovine Serum (FBS) **ATCC Catalog #30-2020**

☒ Falcon® 12-well Clear Flat Bottom TC-treated Multiwell Cell Culture Plate, with Lid, Individually Wr **Corning Catalog #353043**

☒ DMEM, high glucose **Thermo Fisher Scientific Catalog #11965092**

☒ Opti-MEM™ I Reduced Serum Medium **Thermo Fisher Scientific Catalog #31985070**

☒ Right DdCBE Plasmid **addgene Catalog #179686**

☒ Lipofectamine™ 3000 Transfection Reagent **Thermo Fisher Scientific Catalog #L3000008**

☒ Left DdCBE Plasmid **addgene Catalog #179682**

☒ Left Dead (inactive) DdCBE Plasmid **addgene Catalog #179683**

Troubleshooting





Plating of the HEK293T Cells

1 Plating of  HEK293T **ATCC Catalog #CRL-3216**


1.1 The day before transfection, trypsinize and count the cells.

1.2 In a

 Falcon® 12-well Clear Flat Bottom TC-treated Multiwell Cell Culture Plate, with Lid, Individually Wr **Corning Catalog #353043**



, plate 150000 cells per well in  1 mL per well of complete HEK media (

 DMEM, high glucose **Thermo Fisher Scientific Catalog #11965092** with

[M] 10 % volume  Fetal Bovine Serum (FBS) **ATCC Catalog #30-2020** without antibiotics).


Note


Antibiotics can reduce transfection efficiency and were thus omitted.


1.3 Wait for cells to attach  Overnight at  37 °C in a 5% CO₂ tissue culture incubator.

Transfection of DdCBE Plasmids

2 Transfection of DdCBE Plasmids

2.1 For each well of cells to be transfected, dilute  3 µL of






 Lipofectamine™ 3000 Transfection Reagent **Thermo Fisher Scientific Catalog #L3000008**

into  50 µL (total volume) of



Opti-MEM™ I Reduced Serum Medium **Thermo Fisher Scientific Catalog #31985070**

and mix well.

- 2.2 In a separate tube, for each well of cells to be transfected, dilute  2 µg of each DdCBE plasmid  Left DdCBE Plasmid **addgene Catalog #179682** or  Left Dead (inactive) DdCBE Plasmid **addgene Catalog #179683** with  Right DdCBE Plasmid **addgene Catalog #179686** that had been modified to include PuroR marker (left and right, for total of  4 µg plasmid DNA (pDNA))

Note

The DdCBE plasmids used were obtained from Addgene, which included left (Addgene #179682) and right (Addgene #179686) DdCBE plasmids for editing, and a left dead (i.e. inactive) DdCBE plasmid (Addgene #179683) used with the right as a control. For this protocol, the right DdCBE plasmid was modified by replacing the *BSD* gene with *PuroR* to enable dual selection. Please see the associated publication for more plasmid details.

into  50 µL (total volume) of



Opti-MEM™ I Reduced Serum Medium **Thermo Fisher Scientific Catalog #31985070**

. Then add  8 µL P3000 Reagent from



Lipofectamine™ 3000 Transfection Reagent **Thermo Fisher Scientific Catalog #L3000008**

(a 2:1 ratio to DNA) directly to the diluted pDNA. Mix well.





- 2.3 Add the diluted pDNA solution in P3000 reagent (from 2.2) to diluted



Lipofectamine™ 3000 Transfection Reagent **Thermo Fisher Scientific Catalog #L3000008**

(from 2.1), mix, and incubate for  00:15:00 min at room temperature.

15m

- 2.4 Discard the old medium in the well. Add  1 mL complete HEK media ( DMEM, high glucose **Thermo Fisher Scientific Catalog #11965092** with **[M] 10 % volume**  Fetal Bovine Serum (FBS) **ATCC Catalog #30-2020** without antibiotics) to each tube, mix well, and add to the corresponding well. Do this step well by well. Incubate the cells at  37 °C in a 5% CO₂ tissue culture incubator.



Selection of the Transfected Cells

18h

3 Selection of the Transfected Cells

- 3.1 18:00:00 hrs later, replace the medium with complete HEK media (DMEM, high glucose **Thermo Fisher Scientific Catalog #11965092** with 10 % volume Fetal Bovine Serum (FBS) **ATCC Catalog #30-2020** without antibiotics) containing up to 5 ug/mL of Blasticidin S HCl (10 mg/mL) **Thermo Fisher Catalog #A1113903** and 1 ug/mL of Puromycin Dihydrochloride **Thermo Fisher Catalog #A1113803** 18h
- 3.2 Continue selection for 10-14 days and replace the medium every 2 days with complete HEK media containing Blasticidin S HCl (10 mg/mL) **Thermo Fisher Catalog #A1113903** and Puromycin Dihydrochloride **Thermo Fisher Catalog #A1113803** . Ensure drug selection is not finished until all the control untransfected cells are dead. Passage the cells to a larger well-size or flask if needed.
- 3.3 Once selection is finished, maintain the cells in complete HEK media (DMEM, high glucose **Thermo Fisher Scientific Catalog #11965092** with 10 % volume Fetal Bovine Serum (FBS) **ATCC Catalog #30-2020** without antibiotics) for at least 2 days before performing any experiments.

Protocol references

Protocol adapted from Mok, B.Y., et al. A bacterial cytidine deaminase toxin enables CRISPR-free mitochondrial base editing. *Nature* 583, 631–637 (2020), and Mok, B.Y., et al. CRISPR-free base editors with enhanced activity and expanded targeting scope in mitochondrial and nuclear DNA. *Nat Biotechnol* 40, 1378–1387 (2022).